Conclusion

Heartburn and Acid Reflux Cure Program

Curing Heartburn Permanently

Get Instant Access

GER and GERD are frequent conditions in infants, children and adolescents. Symptomatology differs with age, although the main pathophysiological mechanism, transient relaxations of the LES associated with reflux, is identical at all ages. Although infant regurgitation is likely to disappear with age, little is known about reflux. The majority of symptomatic reflux episodes are acid, but non-acid and gas reflux can also cause symptoms. Complications of reflux disease may be severe and even life threatening, such as esophageal stenosis and Barrett's esophagus. There is no gold standard for a diagnostic technique. A simple questionnaire may be among the best diagnostic aids in infants; non-acid reflux is best investigated with impedancometry. Primary GERD is mainly a motility disorder. Guidelines for treatment struggle with the fact that there is no prokinetic drug with a convincing efficacy profile. As a consequence, treatment of GERD focuses on anti-acid drugs, and particularly on PPIs. There is little or no information on how to organize follow-up.

REFERENCES

  1. de Caestecker J. Oesophagus: heartburn. BMJ 2001; 323: 736-739.
  2. Dent J, Brun J, Fendrick AM. An evidence-based appraisal of the reflux disease management - The Genval Workshop Report. Gut 1999; 44: S1-S16.
  3. Rudolph CD, Mazur LJ, Liptak GS et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children. Recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001; 32(Suppl 2): S1-S31.
  4. Vandenplas Y. Oesophageal pH Monitoring for Gastro-oesophageal Reflux in Infants and Children. Chichester, UK: John Wiley and Sons, 1992: 27-36.
  5. Cleveland RH, Kushner DC, Schwartz AN. Gastroesophageal reflux in children: results of a standardized fluoroscopic approach. Am J Roentgenol 1983; 141: 53-56.
  6. Vandenplas Y, Goyvaerts H, Helven R. Gastroesophageal reflux, as measured by 24-hour pH-monitoring, in 509 healthy infants screened for risk of sudden infant death syndrome. Pediatrics 1991; 88: 834-840.
  7. Orenstein SR, Shalaby TM, Cohn J. Reflux symptoms in 100 normal infants: diagnostic validity of the Infant Gastroesophageal Reflux Questionnaire. Clin Pediatr 1996; 35: 607-614.
  8. Chouhou D, Rossignol C, Bernard F, Dupont C. Le reflux gastro-oesophagien dans les centres de bilan de santé de l'enfant de moins de 4 ans. Arch Franc Ped 1992; 49: 843-845.
  9. Nelson SP, Chen EH, Syniar GM. Prevalence of symptoms of gastroesophageal reflux in infancy. Arch Pediatr Adolesc Med 1997; 151: 569-572.
  10. Shepherd R, Wren J, Evans S. Gastroesophageal reflux in children. Clinical profile, course and outcome with active therapy in 126 cases. Clin Pediatr 1987; 26: 55-60.
  11. Nelson SP, Chen EH, Syniar GM. One year follow-up of symptoms of gastroesophageal reflux during infancy. Pediatrics 1998; 102: e67.
  12. Wienbeck M, Barnert J. Epidemiology of reflux disease and reflux esophagitis. Scand J Gastroenterol 1989; 24: 7-13.
  13. Nelson SP, Chen EH, Syniar GM, Christoffel KK. Prevalence of symptoms of gastroesophageal reflux during childhood. Arch Pediatr Adolesc Med 2000; 154: 150-154.
  14. Sonnenberg A, El-Serag HB. Clinical epidemiology and natural history of gastroesophageal reflux disease. Yale J Biol Med 1999; 72: 81-92.
  15. Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann Med 1995; 27: 67-70.
  16. The Jury of the Consensus Conference. French-Belgian Consensus Conference on adult gastro-oesophageal reflux disease 'Diagnosis and Treatment': report of a meeting held in Paris, France, on 21-22 January 1999. Eur J Gastroenterol Hepatol 2000; 12: 129-137.
  17. Nandurkar S, Talley NJ. Epidemiology and natural history of reflux disease. Bailliére's Clin Gastroenterol 2000; 14: 743-757.
  18. Isolauri J, Luostarinen M, Isolauri E. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92: 37-41.
  19. McDougall NJ, Johnston BT, Kee F. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut 1996; 38: 481-486.
  20. El-Serag HB, Bailey NR, Gilger M, Rabeneck L. Endoscopic manifestations of gastroesophageal reflux disease in patients between 18 months and 25 years without neurological deficits. Am J Gastroenterol 2002; 97: 1635-1639.
  21. Lee WS, Beattie RM, Meadows N, Walker-Smith JA. Gastro-oesophageal reflux: clinical profiles and outcome. J Paediatr Child Health 1999; 35: 568-571.
  22. Tolaymat N, Chapman DM. Gastroesophageal reflux disease in children older than two years of age. West Virginia Med J 1998; 94: 22-25.
  23. Treem W, Davis P, Hyams J. Gastroesophageal reflux in the older child: presentation, response to treatment, and long-term follow-up. Clin Pediatr 1991; 30: 435-440.
  24. Hassall E. Co-morbidities in childhood Barrett's esophagus. J Pediatr Gastroenterol Nutr 1997; 25: 255-260.
  25. Voutilainen M, Sipponen P, Macklin JP. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion 2000; 61: 6-13.
  26. Loof L, Gotell P, Elfberg B. The incidence of reflux oesophagitis. Scand J Gastroenterol 1993; 28: 113-118.
  27. Hegar B, Boediarso A, Firmansyah A, Vandenplas Y. Incidence of regurgitation and symptoms of gastroe-sophageal reflux in Indonesian infants. Acta Gastroenterol Belg 2003; Suppl:69 (abstr).
  28. Kang JY, Ho KY. Different prevalences of reflux oesophagitis and hiatus hernia among dyspeptic patients in England and Singapore. Eur J Gastroenterol Hepatol 1999; 11: 845-850.
  29. Kim SL, Hunter JG, Wo JM et al. NSAIDs, aspirin, and esophageal strictures: are over-the-counter medications harmful to the esophagus? J Clin Gastroenterol 1999; 29: 32-34.
  30. Carre IJ, Johnston BT, Thomas PS, Morrisson PJ. Familial hiatal hernia in a large five generation family confirming true autosomal dominant inheritance. Gut 1999; 45: 649-652.
  31. Trudgill NJ, Kapur KC, Riley SA. Familial clustering of reflux symptoms. Am J Gastroenterol 1999; 94: 1172-1178.
  32. Cameron AJ, Lagergren J, Henriksson C. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology 2002; 122: 55-59.
  33. Hu FZ, Preston RA, Post JC. Mapping of a gene for severe pediatric gastroesophageal reflux to chromosome 13q14. JAMA 2000; 284: 325-334.
  34. Orenstein SR, Shalaby TM, Barmada MM, Whitcomb DC. Genetics of gastroesophageal reflux disease: a review. J Pediatr Gastroenterol Nutr 2002; 34: 506-510.
  35. Vandenplas Y, Hassall E. Mechanisms of gastroe-sophageal reflux and gastroesophageal reflux disease. J Pediatr Gastroenterol 2002; 35: 119-136.
  36. Sifrim D, Holloway R, Silny J et al. Acid, non-acid and gas reflux in patients with gastroesophageal reflux disease during 24 hr ambulatory pH-impedance recordings. Gastroenterology 2001; 120: 1588-1598.
  37. McNamara D, O'Morain C. Gastro-oesophageal reflux disease and Helicobacter pylori: an intricate relation. Gut 1999; 45(Suppl 1) :S13-S17.
  38. Graham DY, Yamaoka Y. Disease-specific Helicobacter pylori virulence factors: the unfulfilled promise. Helicobacter 2000; 5(Suppl 1): S3-S9.

Wu JC, Sung JJ, Chan FK et al. Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 427-432. De Koster E. Adverse events of HP eradication: long term negative consequences of HP eradication. Acta Gastroenterol Belg 1998; 61: 350-351. Fallone CA, Barkin AN, Friedman G et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol 2000; 95: 914-920. Van Zanten SJ, Dixon MF, Lee A. The gastric transitional zones: neglected links between gastroduodenal pathology and helicobacter ecology. Gastroenterology 1999; 116: 1217-1229.

Kuiken S, Van Den Elzen B, Tytgat G et al. Evidence for pooling of gastric secretions in the proximal stomach in humans using single photon computed tomography. Gastroenterology 2002; 123: 2157-2158. Fletcher J, Wirz A, Young J et al. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001; 121: 775-783. Dodds WJ, Dent J, Hogan WJ et al. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med 1982; 307: 1547-1552. Omari TI, Benninga MA, Barnett CP et al. Characterization of esophageal body and lower esophageal sphincter motor function in the very premature neonate. J Pediatr 1999; 135: 517-521. Boulant J, Fioramonti J, Dapoigny M et al. Cholecystokinin and nitric oxide in transient lower esophageal sphincter relaxation to gastric distention in dogs. Gastroenterology 1994; 107: 1059-1066. Hirsch DP, Hollowy RH, Tytgat GNJ, Boeckxstaens GE. Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology 1998; 115: 1374-1380.

Sifrim D, Tack J, Lerut T, Janssens J. Transient lower esophageal sphincter relaxations and esophageal body muscular contractile response in reflux esophagitis. Dig Dis Sci 2000; 45: 1293-1300.

Mittal RK, McCallum RW. Characteristics and frequency of transient relaxations of the lower esophageal sphincter in patients with reflux esophagitis. Gastroenterology 1988; 95: 593-599.

Holloway RH, Kocyan P, Dent J. Provocation of transient lower esophageal sphincter relaxations by meals in patients with symptomatic gastroesophageal reflux. Dig Dis Sci 1991; 36: 1034-1039.

Penagini R, Hebbard G, Horowitz M et al. Motor function of the proximal stomach and visceral perception in gastro-oesophageal reflux disease. Gut 1998; 42: 251-257.

Stacher G, Lenglinger J, Bergmann H. Gastric emptying: a contributory factor in gastro-oesophageal reflux activity? Gut 2000; 47: 661-666.

Sifrim D, Holloway R. Transient lower esophageal sphincter relaxations: how many or how harmful? Am J Gastroenterol 2001; 96: 2529-2532. Vela MF, Camacho-Lobato L, Srinivasan R et al. Simultaneous intraesopahgeal impedance and pH measurement of acid and non-acid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120: 1599-1606.

Niemantsverdriet EC, Timmer R, Breumelhof R, Smout AJ. The role of excessive gastro-oesophageal reflux, disordered oesophageal motility and decreased mucosal sensitivity in the pathogenesis of Barrett's oesophagus. Eur J Gastroenterol Hepatol 1997; 9: 515-519. Mathisen B, Worall L, Masel J et al. Feeding problems in infants with gastro-oesophageal reflux disease: a controlled study. J Pediatr Child Health 1999; 35: 163-169.

  1. Black MM, Dubowitz H, Huctheson J. A randomized clinical trial of home intervention for children with failure to thrive. Pediatrics 1995; 95: 807-814.
  2. Burklow KA, Phelps AN, Schultz JR et al. Classifying complex pediatric feeding disorders. J Pediatr Gastroenterol Nutr 1998; 27: 143-147.
  3. Orenstein SR, Cohn JF, Shalaby T. Reliability and validity of an infant gastroesophageal questionnaire. Clin Pediatrics 1993; 32: 472-484.
  4. Heine RG, Jaquiery A, Lubitz L et al. Role of gastro-oesophageal reflux in infant irritability. Arch Dis Child 1995; 73: 121-125.
  5. Snel A, Barnett CP, Cresp TL. Behavior and gastroesophageal reflux in the premature neonate. J Pediatr Gastroenterol Nutr 2000; 30: 18-21.
  6. Hamilton AB, Zeltzer LK. Visceral pain in infants. J Pediatr 1994; 125(Suppl): S95-S102.
  7. Iacono G, Carroccio A, Cavataio F et al. Gastroesophageal reflux and cow's milk allergy in infants: a prospective study. J All Clin Immunol 1996; 97: 822-827.
  8. Salvatore S, Vandenplas Y. Gastroesophageal reflux and cow's milk allergy: is there a link? Pediatrics 2002; 110: 972-984.
  9. Hill DJ, Heine RG, Cameron DJ et al. Role of food protein intolerance in infants with persistent distress attributed to reflux esophagitis. J Pediatr 2000; 136: 641-647.
  10. Orenstein SR, Izadnia F, Khan S. Gastroesophageal reflux disease in children. Gastroenterol Clin North Am 1999; 28: 947-969.
  11. Locke GR, Talley NJ, Fett SL. Prevalence and clinical spectrum of gastroesophageal reflux: a population based study in Olmsted Country, Minnesota. Gastroenterology 1997; 112: 1448-1456.
  12. De Vault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 1434-1442.
  13. Hyman PE. Gastroesophageal reflux: one reason why baby won't eat. J Pediatr 1994; 125: S103-S109.
  14. Holt PG. Parasites, atopy, and the hygiene hypothesis: resolution of a paradox? Lancet 2000; 356: 1699-1701.
  15. Van den Biggelaar AHJ, van Ree R, Rodrigues LC et al. Decreased atopy in children infected with Schistosoma haematobium: a role for parasite-induced interleukins-10. Lancet 2000; 356: 1723-1727.
  16. Louis E, DeLooze D, Deprez P. Heartburn in Belgium: prevalence, impact on daily life, and utilization of medical resources. Eur J Gastroenterol Hepatol 2002; 14: 279-284.
  17. Vandenplas Y. Reflux esophagitis in infants and children. A report from the Working Group of the European Society of Pediatric Gastroenterology and Nutrition on Gastro-oesophageal Reflux Disease. J Pediatr Gastroenterol Nutr 1994; 18: 413-422.
  18. Ahrens P, Noll C, Kitz R et al. Lipid-laden alveolar macrophages: a useful marker of silent aspiration in children. Pediatr Pulmonol 1999; 28: 83-88.
  19. Paterson WG, Murat BW. Combined ambulatory esophageal manometry and dual-probe pH metry in the evaluation of patients with chronic unexplained cough. Dig Dis Sci 1994; 39: 1117-1125.
  20. Bruno G, Graf U, Andreozzi P. Gastric asthma: an unrecognized disease with an unsuspected frequency. J Asthma 1999; 36: 315-325.
  21. Cunningham ET Jr, Ravich WJ, Jones B, Donner MW. Vagal reflexes referred from the upper aerodigestive tract: an infrequently recognized cause of common cardiorespiratory responses. Ann Intern Med 1992; 116: 575-582.
  22. Murphy SG, Yazbeck S, Russo P. Isolated congenital esophageal stenosis. J Pediatr Surg 1995; 30: 1238-1241.
  23. Carre I. The natural history of the partial thoracic stomach ("hiatal hernia") in children. Arch Dis Child 1959; 34: 344-353.
  24. Karnak I, Senocak ME, Tanyel FC, Buyukpamukcu N. Achalasia in childhood: surgical treatment and outcome. Eur J Pediatr Surg 2001; 11: 223-229.
  25. Wienbeck M, Barnert J. Epidemiology of reflux disease and reflux esophagitis. Scand J Gastroenterol 1989; 156: 7-13.
  26. Liacouras CA, Wenner WJ, Brown K, Ruchelli E. Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids. J Pediatr Gastroenterol Nutr 1998; 26: 380-385.
  27. Orenstein SR, Shalaby TM, Di Lorenzo C. The spectrum of pediatric eosinophilic esophagitis beyond infancy: a clinical series of 30 children. Am J Gastroenterol 2000; 95: 1422-1430.
  28. Ruchelli E, Wenner W, Voytek T et al. Severity of esophageal eosinophilia predicts response to conventional gastroesophageal reflux therapy. Pediatr Dev Pathol 1999; 2: 15-18.
  29. Attwood SE, Lewis CJ, Bronder CS et al. Eosinophilic oesophagitis: a novel treatment using Montelukast. Gut 2003; 52: 181-185.
  30. Teitelbaum JE, Fox VL, Twarog FJ et al. Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate. Gastroenterology 2002; 122 : 1216-1225.
  31. Hassall E. Barrett's esophagus: new definitions and approaches in children. J Pediatr Gastroenterol Nutr 1993; 16: 345-364.
  32. Romero Y, Cameron AJ, Locke GR. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal carcinoma. Gastroenterology 1997; 113: 1449-1456.
  33. Krug E, Bergmeijer JH, Dees J. Gastroesophageal reflux and Barrett's esophagus in adults born with esophageal atresia. Am J Gastroenterol 1999; 94: 2825-2828.
  34. Dahms BB, Rothstein FC. Barrett's esophagus in children: a consequence of chronic gastroesophageal reflux. Gastroenterology 1984; 86: 318-323.
  35. Sonnenberg A, El-Serag HB. Clinical epidemiology and natural history of gastroesophageal reflux disease. Yale J Biol Med 1999; 72: 81-92.
  36. Lagergren J, Bergstrom R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831.
  37. Vandenplas Y, de Pont S, Vandemaele C et al. Dependability of esophageal pH monitoring data on software. J Pediatr Gastroenterol Nutr 1996; 23: 203-204.
  38. Vandenplas Y, Helven R, Goyvaerts H. Comparative study of glass and antimony electrodes for continuous oesophageal pH monitoring. Gut 1991; 32: 708-712.
  39. Kaynard A, Flora K. Gastroesophageal reflux disease. Control of symptoms, prevention of complications. Postgrad Med 2001; 110: 42-44.
  40. Vandenplas Y, Belli D, Benhamou P et al. A critical appraisal of current management practicies for infant regurgitation - recommendations of a working party. Eur J Pediatr 1997; 156: 343-357.
  41. Ewer AK, James ME, Tobin JM. Prone and left lateral positioning reduce gastro-oesophageal reflux in preterm infants. Arch Dis Child Fetal Neonatal Ed 1999; 81: F201-F205.
  42. Khoshoo V, Ross G, Brown S, Edell D. Smaller volume, thickened formulas in the management of gastroe-

sophageal reflux in thriving infants. J Pediatr Gastroenterol Nutr 2000; 31: 554-556.

  1. Carroll AE, Garrison MM, Christakis DA. A systematic review of nonpharmacological and nonsurgical therapies for gastroesophageal reflux in infants. Arch Pediatr Adolesc Med 2002; 156: 109-113.
  2. Bosscher D, van Caillie-Bertrand M, van Dyck K. Thickening of infant formula with digestible and indigestible carbohydrate availability of calcium, iron and zinc in vitro. J Pediatr Gastroenterol Nutr 2000; 30: 373378.
  3. Aggett PJ, Agostoni C, Goulet O et al. Antireflux or anti-regurgitation milk products for infants and young children: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2002; 34: 496-498.
  4. Levtchenko E, Hauser B, Vandenplas Y. Nutritional value of an 'anti-regurgitation' formula. Acta Gastroenterol Belg 1998; 61: 285-287.
  5. Vandenplas Y. Clinical use of cisapride and its risk-benefit in paediatric patients. Eur J Gastroenterol Hepatol 1998; 10: 871-881.
  6. Aravindhan N, Chisholm DG. Sulfhemoglobinemia presenting as pulse oximetry desaturations. Anesthesiology 2000; 93: 883-884.
  7. Cinquetti M, Bonetti P, Bertamini P. Current role of anti-dopaminergic drugs in pediatrics. Pediatr Med Chir 2000; 22 : 1-7.
  8. Chou CC, Wu D. Torsade de pointes induced by meto-clopramide in an elderly woman with preexisting complete left bundle branch block. Chang Gubng Med J 2001; 4: 805-809.
  9. Patterson D, Abell T, Rothstein R et al. A double-blind multicenter comparison of domperidone and metoclo-pramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999; 94: 1230-1234.
  10. Barone JA. Domperidone: a peripherally acting dopamine 2-receptor antagonist. Ann Pharmacother 1999; 33: 429-440.
  11. Lu F, Wu H, Zhang K, Li D. Domperidone and hyperpro-lactinemia. Human Yi Ke Da Xue Xue Bao 1998; 23: 100-102.
  12. Drolet B, Rousseau G, Daleau P et al. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 2000; 102: 1883-1885.
  13. Cameron HA, Reyntjes AJ, Lake-Bakaar G. Cardiac arrest after treatment with intravenous domperidone. BMJ 1985; 290: 160.
  14. Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pylori stenosis. J Pediatr 2001; 139: 380-384.
  15. Mishra A, Friedman HS, Sinha AK. The effects of erythromycin on the electrocardiogram. Chest 1999; 115: 983-986.
  16. Guerin JM, Leibinger F. Why not use erythromycin in GI motility? Chest 2002; 121: 301.
  17. Gay K, Baughan W, Miller J. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J Infect Dis 2000; 182: 1417-1424.
  18. Vandenplas Y, and the ESPGHAN Cisapride Panel. Current pediatric indications for cisapride. J Pediatr Gastroenterol 2000; 31: 480-489.
  19. Rode H, Millar AJW, Melis J, Cywes S. Esophageal assessment of gastroesophageal reflux in 18 patients and the effect of two prokinetic agents: cisapride and metoclopramide. J Pediatr Surg 1987; 22: 931-934.

Augood C, MacLennan S, Gilbert R, Logan S. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst Rev 2000; 3: CD002300. Shulman RJ. Report from the NASPGN therapeutics subcommittee. Cisapride and the attack of the P-450s. J Pediatr Gastroenterol Nutr 1996; 23: 395-397. Desta Z, Zoukhova N, Mahal SK, Flockhart DA. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos 2000; 28: 789-800.

Viskin S. Long QT syndromes and torsades de pointes. Lancet 1999; 354: 1625-1633. Tonini M, De Ponti F, Di Nucci A, Crema F. Review article: cardiac adverse effects of gastrointestinal proki-netics. Aliment Pharmacol Ther 1999; 13: 1585-1591. Hill SL, Evangelista JK, Pizzi AM et al. Proarrhythmia associated with cisapride in children. Pediatrics 1998; 101: 1053-1056.

Ward RM, Lemons JA, Molteni RA. Cisapride: a survey of the frequency of use and adverse events in premature newborns. Pediatrics 1999; 103: 469-472. Levy J, Hayes C, Kern J et al. Does cisapride influence cardiac rhythm? Results of a US multicenter, doubleblind, placebo controlled pediatric study. J Pediatr Gastroenterol Nutr 2001; 32: 458-463. Tutar HE, Kansu A, Kalayci AG et al. Effects of cisapride on ventricular repolarization in children. Acta Paediatr 2000; 89: 820-823.

Semama DS, Bernardini S, Louf S et al. Effects of cisapride on QTc interval in term neonates. Arch Dis

Child Fetal Neonat Ed 2001; 84: F44-F46.

Benatar A, Feenstra A, De Craene T, Vandenplas Y. QTc interval in infants and serum concentrations. J Pediatr

Gastroenterol Nutr 2001; 33: 41-46.

Benatar A, Feenstra A, Decraene T, Vandenplas Y.

Effects of cisapride on corrected QT interval, heart rate, and rhythm in infants undergoing polysomnography.

Pediatrics 2000; 106: E85.

Cools F, Benatar A, Bruneel E et al. A comparison of the pharmacokinetics of two dosing regimens of cisapride and their effects on corrected QT interval in premature infants. Eur J Clin Pharmacol. 2003; 59: 17-22. Kivisto KT, Lilja JJ, Backman JT, Neuvonen PJ. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin Pharmacol Ther 1999; 66: 448-453.

Napolitano C, Schwartz PJ, Brown AM et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000; 11: 691-696. Walker AM, Szneke P, Weatherby LB et al. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 1999; 107: 356-362.

Augood C, Gilbert R, Logan S, MacLennan S. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst Rev 2002; 3: CD002300. Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003; 67: 82-89. Culy CR, Bhana N, Plosker GL. Ondansetron: a review of its use as an antiemetic in children. Paediatr Drugs 2001; 3: 441-79.

Wagstaff A, Frampton J, Croom K. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women. Drugs 2003; 63: 1101-1120.

  1. Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 1503-1509.
  2. Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA(B) agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 2003; 52: 464-470.
  3. Wiersma HE. Pharmacokinetics of a single oral dose of baclofen in pediatric patients with GERD. Ther Drug Monitor 2003; 25: 93-98.
  4. Vandenplas Y, Belli DC, Benatar A et al. The role of cisapride in the treatment of pediatric gastroesophageal reflux. The European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 1999; 28: 518-528.
  5. Flockhart DA, Desta Z, Mahal SK. Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions. Clin Pharmacokinet 2000; 39: 295-309.
  6. Bachmann KA, Sullivan TJ, Jauregui L et al. Drug interactions of H2-receptor antagonists. Scand J Gastroenterol 1994; 206 (Suppl): 14-19.
  7. Paul K, Redman CM, Chen M. Effectiveness and safety of nizatidine, 75 mg, for the relief of episodic heartburn. Aliment Pharmacol Ther 2001; 15: 1571-1577.
  8. Sabesin SM. Safety issues relating to long-term treatment with histamine H2-receptor antagonists. Aliment Pharmacol 1993; 7(Suppl 2): S35-S40.
  9. Kelly DA. Do H2 receptor antagonists have a therapeutic role in childhood? J Pediatr Gastroenterol 1994; 19: 270-276.
  10. Adachi N, Seyfried FJ, Arai T. Blockade of central hista-minergic H2-receptors aggravates ischemic neuronal damage in gerbil hippocampus. Crit Care Med 2001; 29: 1189-1194.
  11. Emovon OE, King JA, Holt CO, Browne BJ. Ranitidine induced acute interstitial nephritis in a cadaveric renal allograft. Am J Kidney Dis 2001; 38: 169-172.
  12. Boehning W. Effect of cimetidine and ranitidine on plasma theophylline in patients with chronic obstructive airways disease treated with theophylline and corti-costeroids. Eur J Clin Pharmacol 1990; 38: 43-45.
  13. Alliet P, Devos E. Ranitidine-induced bradycardia in a neonate - secondary to a congenital long QT interval syndrome. Eur J Pediatr 1993; 152: 933-934.
  14. Hu WH, Wang KY, Hwang DS et al. Histamine 2 receptor blocker - ranitidine and sinus mode dysfunction. Zhonghua YiXue Za Zhi 1997; 60: 1-5.
  15. Nault MA, Milne B, Parlow JL. Effects of the selective H1 and H2 histamine receptor antagonists loretadine and ranitidine on autonomic control of the heart. Anesthesiology 2002; 96: 336-341.
  16. Ooie T, Saaikawa T, Hara M et al. H2-blocker modulates heart rate variability. Heart Vessels 1999; 14: 137-142.
  17. Basit AW, Newaton JM, Lacey LF. Susceptibility of the H2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora. Int J Pharm 2002; 237: 23-33.
  18. Cothran DS, Borowitz SM, Sutphen JL et al. Alteration of normal gastric flora in neonates receiving ranitidine. J Perinatol 1997; 17: 383-388.
  19. Messori A, Trippoli S, Vaiani M et al. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analy-sis of randomised controlled trials. BMJ 2000; 321: 1103-1106.
  20. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol 2001; 15: 355-370.
  21. Londong W, Phillips J, Johnson NJ, Wood JR. The effect of combined therapy with ranitidine and pirenzipine in the treatment of reflux esophagitis. Aliment Pharmacol Ther 1992; 6: 609-618.
  22. Vakil NB, Shaker R, Johnson DA et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927-935.
  23. Jones R, Bytzer P. Acid suppression in the management of gastro-oesophageal reflux disease - an appraisal of treatment options in primary care. Aliment Pharmacol Ther 2001; 16: 765-771.
  24. Ferron GM, Preston RA, Noveck RJ et al. Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. Clin Ther 2001; 23: 1180-1192.
  25. James LP, Kearns GL. Pharmacokinetics and pharmaco-dynamics of famotidine in paediatric patients. Clin Pharmacokinetic 1996; 31: 103-110.
  26. Scott LJ. Lansoprazole: in the management of gastroesophageal reflux disease in children. Paediatr Drugs 2003; 5: 57-61.
  27. Zimmermann AE, Walters JK, Katona BG et al. A review of omeprazole use in the treatment of acid-related disorders in children. Clin Ther 2001; 23: 660-679.
  28. Leufkans H, Claessens A, Heerdink E et al. A prospective follow-up study of 5669 users of lansoprazole in daily practice. Aliment Pharmacol Ther 1997; 11: 887-897.
  29. Castot A, Bidault I, Dahan R, Efthymiou ML. Evaluation of unexpected and toxic effects of omeprazole A90 -reported to the regional centers of pharmacovigilance during the first 22 postmarketing months. Therapie 1993; 48: 469-474.
  30. Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000; 6(9 Suppl): S491-505.
  31. Andersson T, Hanssan-alin M, Hasselgren G, Rohss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 523-537.
  32. ter Heide H, Hendriks HJ, Heijmans H et al. Are children with cystic fibrosis who are treated with a protonpump inhibitor at risk for vitamin B12 deficiency? J Pediatr Gastroenterol Nutr 2001; 33: 342-345.
  33. Singh P, Indaram A, Greenberg R et al. Long term omeprazole therapy for reflux esophagitis: follow-up in serum gastrin levels, EC cell hyperplasia and neoplasia. World J Gastroenterol 2000; 6: 789-792.
  34. Nuanton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000; 25: 333-338.
  35. Amaro R, Montelongo PC, Barkin JS. Sucralfate-induced diarrhea in an enterally fed patient. Am J Gastroenterol 1999; 94: 2328-2329.
  36. Guy C, Ollagnier M. Sucralfate and bezoars: data from the system of pharmacologic vigilance and review of the literature. Therapie 1999; 54: 55-58.
  37. Hemstreet BA. Use of sucralfate in renal failure. Ann Pharmacother 2001; 35: 360-364.
  38. Fleming GF, Vokes EE, McEvilly JM et al. Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis. Cancer Chemother Pharmacol 1991; 28: 226-227.
  39. Talley NJ, Verlinden M, Snape W et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000; 14: 1653-1661.
  40. Mahmood Z, McMahon BP, Arfin Q et al. Endocinch therapy for gastro-oesophageal reflux disease: a one year prospective follow up. Gut 2003; 52: 34-39.
  41. Wolfsen HC, Richards WO. The Stretta procedure for the treatment of GERD: a registry of 558 patients. J Laparoendosc Adv Surg Tech A 2002; 12: 395-402.
  42. Johnson DA, Ganz R, Aisenberg J et al. Endoscopic, deep mural implantation of enteryx for the treatment of GERD: 6-month follow-up of a multicenter trial. Am J Gastroenterol 2003; 98: 250-258.
  43. Galmiche JP, Bruley des Varannes S. Endoluminal therapies for gastro-oesophageal reflux disease. Lancet 2003; 361: 1119-1121.
  44. Fonkalsrud EX, Bustorff-Silva J, Perez CA et al. Antireflux surgery in children under three months of age. J Pediatr Surg 1999; 34: 527-531.
  45. Pearl RH, Robie DK, Ein SH et al. Complications of gastroesophageal reflux surgery in neurologically impaired versus neurologically normal children. J Pediatr Surg 1990; 25: 1169-1173.
  46. Alexander F, Wyllie R, Jirousek K et al. Delayed gastric emptying affects outcome of Nissen fundoplication in neurologically impaired children. Surgery 1997; 122: 690-697.
  47. Spitz L, Roth K, Kiely EM et al. Operation for gastro-oesophageal reflux associated with severe mental retardation. Arch Dis Child 1993; 68: 347-351.
  48. Booth MI, Jones L, Stratford J, Dehn TC. Results of laparoscopic Nissen fundoplication 8 years after surgery. Br J Surg 2002; 89: 476-481.
  49. Bergmeijer JH, Harbers JS, Molenaar JC. Function of pediatric Nissen-Rosetti fundoplication followed up into adolescence and adulthood. J Am Coll Surg 1997; 184: 259-261.
  50. Burd RS, Price MR, Whalen TV. The role of protective antireflux procedures in neurologically impaired children: a decision analysis. J Pediatr Surg 2002; 37: 500506.

Was this article helpful?

0 0
Relaxation Audio Sounds Relaxation

Relaxation Audio Sounds Relaxation

This is an audio all about guiding you to relaxation. This is a Relaxation Audio Sounds with sounds called Relaxation.

Get My Free MP3 Audio


Post a comment